- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Overland Park Today
By the People, for the People
Parnell Launches First FDA-Approved Generic Florfenicol + Flunixin Combination for BRD
nixiFLOR� injectable solution aims to provide new treatment option for bovine respiratory disease.
Apr. 1, 2026 at 6:02pm
Got story updates? Submit your updates here. ›
Parnell Technologies Pty. Ltd., a pharmaceutical company, has announced the U.S. launch of nixiFLOR� (florfenicol and flunixin meglumine) injectable solution, the first FDA-approved generic combination of these two drugs for the treatment of bovine respiratory disease (BRD) in cattle.
Why it matters
The launch of nixiFLOR� provides cattle producers and veterinarians with a new, more affordable treatment option for BRD, which is one of the most common and costly diseases affecting the beef and dairy industries. The combination of florfenicol and flunixin meglumine in a single injectable solution can help simplify treatment protocols and potentially improve outcomes for cattle with BRD.
The details
nixiFLOR� is a generic version of Banamine� (flunixin meglumine) and Nuflor� (florfenicol), two widely used medications for the treatment of BRD. The combination product is designed to provide anti-inflammatory and antimicrobial properties in a single injection, potentially reducing the number of injections required and improving compliance.
- nixiFLOR� was recently approved by the FDA for the treatment of BRD in cattle.
The players
Parnell Technologies Pty. Ltd.
A pharmaceutical company that develops and markets animal health products, including the newly launched nixiFLOR� injectable solution for bovine respiratory disease.
What’s next
Parnell plans to make nixiFLOR� widely available to cattle producers and veterinarians across the United States in the coming months.
The takeaway
The launch of nixiFLOR� provides cattle producers with a new, more affordable treatment option for bovine respiratory disease, which is a significant health and economic challenge for the beef and dairy industries.
